Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Innovent Biologics's Enterprise Value is €15,350 Mil.
Innovent Biologics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €1,130 Mil. Therefore, Innovent Biologics's EV-to-FCF for today is 13.59.
The historical rank and industry rank for Innovent Biologics's EV-to-FCF or its related term are showing as below:
STU:6IB'
s EV-to-FCF Range Over the Past 10 Years
Min: -363.55 Med: -17.43 Max: 13.73
Current: 13.32
During the past 10 years, the highest EV-to-FCF of Innovent Biologics was 13.73. The lowest was -363.55. And the median was -17.43.
STU:6IB's EV-to-FCF is ranked better than 52.68% of 336
companies
in the Biotechnology industry
Industry Median: 15.16
vs STU:6IB: 13.32
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Innovent Biologics's PE Ratio (TTM) for today is calculated as:
Innovent Biologics's share price for today is €9.692.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Innovent Biologics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €0.055.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Innovent Biologics EV-to-FCF Related Terms
Innovent Biologics EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Innovent Biologics's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Innovent Biologics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Innovent Biologics EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Innovent Biologics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Innovent Biologics's EV-to-FCF falls into.
Innovent Biologics's current Enterprise Value is €15,350 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Innovent Biologics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €1,130 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Innovent Biologics (STU:6IB) has a EV-to-FCF of 13.59 as of Jul. 20, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Innovent Biologics and its competitors. According to the industry distribution chart, Innovent Biologics ranks #159 out of 336 companies in the Biotechnology industry, placing it in the top 47.3%.
Is Innovent Biologics' EV-to-FCF too high?
Innovent Biologics' current EV-to-FCF is 13.59. The Biotechnology industry median EV-to-FCF is 15.16. Innovent Biologics' value of 13.59 is 10.4% below this industry median. Based on the distribution chart, Innovent Biologics ranks #159 out of 336 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Innovent Biologics has a GF Score™ of 80/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Innovent Biologics' EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Innovent Biologics ranks #159 out of 336 companies for EV-to-FCF. This puts Innovent Biologics in the upper half of its industry. The industry median EV-to-FCF is 15.16. Innovent Biologics' value of 13.59 is 10.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 15.16, based on 336 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Innovent Biologics's current EV-to-FCF of 13.59 is 10.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Innovent Biologics and its competitors. For the Biotechnology industry, the median EV-to-FCF is 15.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Innovent Biologics's current EV-to-FCF is 13.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Innovent Biologics stock overvalued right now?
Based on GuruFocus' analysis, Innovent Biologics (STU:6IB) is currently considered Modestly Undervalued. The stock's GF Value™ is €11.19, compared to a current price of €9.69 — trading 13.4% below its estimated fair value. The current EV-to-FCF is 13.59 and 10.4% below the Biotechnology industry median of 15.16. Innovent Biologics' overall GF Score™ is 80/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Innovent Biologics (STU:6IB), the current EV-to-FCF is 13.59 as of Jul. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Innovent Biologics (STU:6IB) Overvalued in 2026?
Based on GuruFocus' analysis, Innovent Biologics stock appears to be undervalued.
The current stock price of €9.69 is trading 13.4% below its estimated GF Value™ of €11.19.
GuruFocus considers Innovent Biologics to be Modestly Undervalued.
Key valuation signals for STU:6IB:
EV-to-FCF: 13.59
GF Value™: €11.19 vs. price of €9.69 (13.4% below fair value)
Industry Position: 10.4% below the Biotechnology median (#159 of 336)
No single metric tells the full story. See the STU:6IB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Innovent Biologics is one of the leading biotechnology companies in China. Listed on the Hong Kong stock exchange in 2018, Innovent has 12 commercialized oncology products and four commercialized nononcology products as of January 2026, and 34 drugs in its research and development pipeline. Its core assets are Tyvyt, a PD-1 inhibitor included in the National Reimbursement Drug Lists (NRDL) for the first-line treatment of five major cancers, and mazdutide, a GLP-1/glucagon dual agonist drug for weight loss, fat breakdown, and Type 2 diabetes. Mazdutide is the first domestic GLP-1 drug produced and competes with Eli Lilly and Novo Nordisk in China. Tyvyt's main competition includes drugs from Junshi, Jiangsu Hengrui, BeOne, Merck, and Bristol Myers.
80GF Score
Get the complete analysis for STU:6IB
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:6IB has been successfully added to your 
